Plancorp LLC Has $1.96 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 30th, 2023

Plancorp LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,655 shares of the company’s stock after selling 251 shares during the period. Plancorp LLC’s holdings in Johnson & Johnson were worth $1,962,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Moneta Group Investment Advisors LLC increased its holdings in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter valued at $4,609,399,000. Morgan Stanley increased its holdings in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares in the last quarter. Finally, Savant Capital LLC increased its holdings in Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock valued at $29,637,000 after purchasing an additional 3,588,251 shares in the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ opened at $164.31 on Wednesday. The business’s 50-day moving average price is $166.68 and its two-hundred day moving average price is $161.50. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a market capitalization of $427.04 billion, a price-to-earnings ratio of 33.26, a P/E/G ratio of 2.76 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the business posted $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 22nd. Atlantic Securities increased their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Finally, Citigroup began coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target on the stock. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Hold” and an average price target of $171.80.

Read Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.